GlassScriptPhysician profile
Eleanor Lam
NPI 1316166804
$1,720.19
in general payments reported to CMS, 2019-2025
15 companies · $287 in 2025
The $287 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $371 · 2020: $142 · 2021: $57.58 · 2022: $87.33 · 2023: $441 · 2024: $335 · 2025: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,063.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,063.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $868.00 | 2019-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $185.12 | 2019-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $163.27 | 2019-2024 | |
| Amgen INC. | $122.30 | 2019-2024 | Prolia, Evenity |
| Beta Bionics, INC. | $110.23 | 2023 | Ilet Bionic Pancreas |
| Dexcom, INC. | $65.06 | 2023-2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $45.70 | 2020 | |
| Madrigal Pharmaceuticals | $27.73 | 2025 | Rezdiffra |
| Sequel Med Tech, LLC | $24.27 | 2025 | Twiist |
| Medtronic, INC. | $24.24 | 2025 | Minimed 780g |
| Tandem Diabetes Care, INC. | $21.49 | 2020 | |
| Ascendis Pharma Endocrinology INC | $18.98 | 2025 | Yorvipath |
| Emd Serono, INC. | $15.23 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.68 | 2019 | |
| Ascensia Diabetes Care US INC. | $13.89 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eleanor Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.